Shilpa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHILPA
SHILPA has fifteen approved drugs.
There are five US patents protecting SHILPA drugs. There are two tentative approvals on SHILPA drugs.
There are fifty-five patent family members on SHILPA drugs in twenty-six countries and fifty-two supplementary protection certificates in sixteen countries.
Summary for Shilpa
| International Patents: | 55 |
| US Patents: | 5 |
| Tradenames: | 13 |
| Ingredients: | 13 |
| NDAs: | 15 |
| Patent Litigation for Shilpa: | See patent lawsuits for Shilpa |
Drugs and US Patents for Shilpa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa | IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 208302-001 | Jan 17, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shilpa | GEMCITABINE HYDROCHLORIDE | gemcitabine hydrochloride | INJECTABLE;INJECTION | 207575-001 | Feb 22, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-003 | Dec 22, 2015 | AP | RX | Yes | Yes | 10,842,770 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Shilpa | APREMILAST | apremilast | TABLET;ORAL | 211774-003 | Apr 7, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-002 | Dec 22, 2015 | AP | RX | Yes | Yes | 10,842,770 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shilpa Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2015003824 | ⤷ Start Trial |
| Brazil | 112015006692 | ⤷ Start Trial |
| Japan | 5824511 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016151365 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2011139899 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shilpa Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1591122 | 132013902140458 | Italy | ⤷ Start Trial | PRODUCT NAME: ACIDO ZOLEDRONICO(ACLASTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/05/308/002, 20071003;57363, 20070927 |
| 0564409 | SPC/GB02/016 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108 |
| 2962690 | LUC00125 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/14/981 20150116 |
| 1746976 | LUC00026 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
| 1746976 | C01746976/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IRINOTECAN SUCROSOFAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65994 25.07.2017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
